Equities research analysts at StockNews.com initiated coverage on shares of Trevena (NASDAQ:TRVN – Get Free Report) in a research note issued to investors on Saturday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.
Trevena Trading Down 14.7 %
Shares of NASDAQ:TRVN opened at $4.01 on Friday. Trevena has a 12-month low of $3.35 and a 12-month high of $25.75. The business’s fifty day simple moving average is $2.72 and its 200-day simple moving average is $1.21. The company has a market capitalization of $73.55 million, a PE ratio of -1.50 and a beta of 1.03.
Trevena (NASDAQ:TRVN – Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.36. The company had revenue of $0.33 million during the quarter.
Institutional Inflows and Outflows
About Trevena
Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.
Read More
- Five stocks we like better than Trevena
- Trading Halts Explained
- 3 Stocks That Could Rise on European Bank Interest Rate Cuts
- How to Effectively Use the MarketBeat Ratings Screener
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- Comparing and Trading High PE Ratio Stocks
- MarketBeat Week in Review – 9/16 – 9/20
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.